Belite Bio, Inc (BLTE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 4:00 PM EDT
Company Participants
Hendrik Scholl – Chief Medical Officer
Hao-Yuan Chuang – CFO & Director
Presentation
Unknown Analyst
Great. Welcome, everyone. By way of quick introduction, I’m [ Will Hung, ] Senior VP of Investment Banking at Biotech. Thrilled today to welcome Hendrik Scholl, CMO of Belite; and Hao-Yuan Chuang, CFO of Belite. As a quick background on Hendrik, Hao-Yuan and as well as Belite. Hendrik has served as the Chief Medical Officer of Belite Bio since September 2024. He is a clinically active retinal expert with more than 2 decades of expertise in treating retinal diseases, including Stargardt disease and age-related macular degeneration. Dr. Scholl is the coordinating principal investigator of the largest natural history study in Stargardt disease.
And then Hao-Yua. Hao-Yua has served as the CFO of Belite Bio since April 2020. Prior to joining Belite Bio, Mr. Chuang served as Chief Financial Officer of Lin BioScience. Belite Bio is a clinical stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases, including Stargardt disease and geographic atrophy. The company’s lead asset is Tinlarebant LBS 008, a novel oral RBP4 antagonist that has initiated rolling NDA submission. Thank you both for joining.
Question-and-Answer Session
Unknown Analyst
Thank you for having us. All right. Well, to start, could you walk us through the mechanism of action and why targeting RBP4 is the right approach for both Stargardt and GA?
Hendrik Scholl
Chief Medical Officer
Happy to. So both diseases are extremely similar in phenotypic expression. It’s just that Stargardt disease starts very early. It’s a pediatric or disease of the adolescent patient, while age-related macular degeneration, therefore, the name, is age-related and is a disease of the elderly. Both diseases affect the macula. And in both diseases, what you
You must be logged in to post a comment Login